AML – acute myeloid leukaemia
CD123 expression
bispecific antibody (bsAb)
myelodysplastic and myeloproliferative syndromes
venetoclax (BCL2 inhibitor)
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
31
10
2021
accepted:
21
12
2021
entrez:
31
1
2022
pubmed:
1
2
2022
medline:
1
2
2022
Statut:
epublish
Résumé
APVO436 is a recombinant bispecific antibody designed to direct host cytotoxic T-cells to CD123-expressing blast cells in patients with hematologic malignancies. APVO436 showed promising tolerability and single-agent activity in relapsed or refractory (R/R) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The primary purpose of this
Identifiants
pubmed: 35096610
doi: 10.3389/fonc.2021.806243
pmc: PMC8793782
doi:
Types de publication
Journal Article
Langues
eng
Pagination
806243Informations de copyright
Copyright © 2022 Watts, Lin, Mims, Patel, Lee, Shahidzadeh, Shami, Cull, Cogle, Wang and Uckun.
Déclaration de conflit d'intérêts
Author FU is employed by Ares Pharmaceuticals, he served as a consultant for Aptevo Therapeutics and he serves as a consultant to Reven Pharmaceuticals. Author CL is employed by Oncotelic Therapeutics, she served as a consultant to Aptevo Therapeutics and she serves as a consultant to Reven Pharmaceuticals. Author AS also served as a consultant to Aptevo. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Blood Cancer J. 2020 Oct 30;10(10):107
pubmed: 33127875
Cancers (Basel). 2019 Dec 26;12(1):
pubmed: 31888052
Nat Med. 2018 Dec;24(12):1859-1866
pubmed: 30420752
Blood. 2020 Jan 9;135(2):85-96
pubmed: 31765470
Blood. 2021 Feb 11;137(6):751-762
pubmed: 32929488
Cancers (Basel). 2019 Feb 14;11(2):
pubmed: 30769877
Leukemia. 2021 Jul;35(7):1843-1863
pubmed: 33953290
Cell Stem Cell. 2009 Jul 2;5(1):31-42
pubmed: 19570512
Cancer Cell. 2018 Nov 12;34(5):724-740.e4
pubmed: 30423294
Future Oncol. 2021 Aug;17(23):2989-3005
pubmed: 34024158
Blood. 2019 Jan 3;133(1):7-17
pubmed: 30361262
Blood. 2002 Oct 15;100(8):2980-8
pubmed: 12351411
Blood. 2020 Jul 9;136(2):199-209
pubmed: 32325491
Ann Hematol. 2012 Oct;91(10):1541-6
pubmed: 22669506
Haematologica. 2011 Dec;96(12):1792-8
pubmed: 21933861
Cell Stem Cell. 2013 Mar 7;12(3):329-41
pubmed: 23333149
Curr Opin Oncol. 2017 Nov;29(6):467-473
pubmed: 28857842
Front Oncol. 2021 May 10;11:656218
pubmed: 34041025
Blood. 2021 Jul 22;138(3):234-245
pubmed: 34292323
Cancer. 2020 Nov 1;126(21):4668-4677
pubmed: 32767757
Lancet Oncol. 2018 Feb;19(2):216-228
pubmed: 29339097
Cancer Discov. 2020 Apr;10(4):506-525
pubmed: 32014868
Hemasphere. 2021 Mar 09;5(4):e549
pubmed: 33718803
Cancers (Basel). 2021 Oct 21;13(21):
pubmed: 34771451
Acta Haematol. 2017;138(3):175-181
pubmed: 29065396
Cell Death Dis. 2020 Nov 2;11(11):941
pubmed: 33139702
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Am J Hematol. 2018 Mar;93(3):401-407
pubmed: 29218851
Curr Opin Hematol. 2019 Mar;26(2):88-95
pubmed: 30640734
N Engl J Med. 2020 Aug 13;383(7):617-629
pubmed: 32786187
Cancers (Basel). 2021 Aug 15;13(16):
pubmed: 34439266